Christophe Lançon

Christophe Lançon

Auto-generated profile, based on publicly available information

Christophe Lançon

EA 3279: CEReSS, Health Service Research and Quality of Life Center, Aix Marseille University, 27, boulevard Jean-Moulin, 13005 Marseille, France; Department of University Psychiatry « Solaris », AP-HM, Sainte Marguerite University Hospital, 270, boulevard de Sainte-Marguerite, 13009 Marseille, France

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 September 2018 in The Journal of Clinical Psychiatry
Verified
Journal Article
Closed access
PDF file
OGOphélia Godin
Ophélia Godin
MLMarion Leboyer
Marion Leboyer
FSFrank Schürhoff
Frank Schürhoff
PLPierre-Michel Llorca
Pierre-Michel Llorca
Laurent BoyerLaurent Boyer
Laurent Boyer
FGfor the FACE-SZ (FondaMental Academic Centers of Expertise for Schizophrenia) Group
for the FACE-SZ (FondaMental Academic Centers of Expertise for Schizophrenia) Group
From The Journal of Clinical Psychiatry: Cardiovascular diseases are the primary cause of mortality in individuals with schizophrenia, yet no study has yet explored the impact of metabolic syndrome on schizophrenia relapse. This study explored the effect that several risk factors—including metabolic syndrome—have on schizophrenia relapse.

10 October 2014 in Current Medical Research and Opinion
Verified
Journal Article
Closed access
PLPierre-Michel Llorca
Pierre-Michel Llorca
CLChristophe Lançon
Christophe Lançon
MBMélanie Brignone
Mélanie Brignone
BRBenoît Rive
Benoît Rive
SSSamir Salah
Samir Salah
CFClément Francois
Clément Francois
Vortioxetine is an antidepressant with multimodal activity which has shown efficacy in major depressive disorder (MDD) patients in six of ten short-term, randomized, placebo-controlled trials (completed end 2012). We performed meta-regression analyses to indirectly compare vortioxetine to seven marketed antidepressants with different mechanisms of action. To ensure study comparability, only experimental drug and placebo arms from placebo-controlled registration studies were included in primary analyses. The main outcomes were efficacy (standardized mean difference in change from baseline to 2 months on primary endpoint [MADRS/HAM-D]), and tolerability (withdrawal rate due to adverse events). For efficacy, estimates of treatment effect (negative estimates favor vortioxetine) for vortioxetine versus comparators were: agomelatine, -0.16 (p = 0.11); desvenlafaxine, 0.03 (p = 0.80); duloxetine, 0.09 (p = 0.42); escitalopram, -0.05 (p = 0.70); sertraline, -0.04 (p = 0.83); venlafaxine IR/XR, 0.12 (p = 0.33); and vilazodone, -0.25 (p = 0.11). For tolerability, all but one combination was numerically in favor of vortioxetine (odds ratio < 1), although not all differences were statistically significant: agomelatine, 1.77 (p = 0.03); desvenlafaxine, 0.58 (p = 0.04); duloxetine, 0.75 (p = 0.26); escitalopram, 0.67 (p = 0.28); sertraline, 0.30 (p = 0.01); venlafaxine, 0.47 (p = 0.01); and vilazodone, 0.64 (p = 0.18). Sensitivity analyses did not significantly alter antidepressant effect estimates or relative ranking. These meta-regression data show that vortioxetine offers a comparable or favorable combination of efficacy (measured by MADRS/HAM-D) and tolerability (measured by withdrawal rate due to adverse events) versus other antidepressants in registration studies in MDD. Alternative methods like mixed-treatment comparison and inclusion of all randomized studies and active reference arms may provide complementary information to this analysis (more evidence but also more heterogeneity). Key messages: Indirect comparisons based on registration studies allow a useful comparison between a recently approved antidepressant and an approved drug. Vortioxetine offers a comparable or favorable combination of efficacy (measured by MADRS/HAM-D assessments) and tolerability (measured by withdrawal rate due to adverse events) versus other antidepressants in registration studies in MDD.

1 March 2016 in La Presse Médicale
Verified
Journal Article
Closed access
JHJérôme Holtzmann
Jérôme Holtzmann
RRRaphaëlle Richieri
Raphaëlle Richieri
GSGhassen Saba
Ghassen Saba
NANajib Allaïli
Najib Allaïli
RBRémy Bation
Rémy Bation
EHEmmanuel Haffen
Emmanuel Haffen

11 February 2025 in Dialogues in clinical neuroscience
Verified
Journal Article
Open access
TKThéo Korchia
Théo Korchia
MFMelanie Faugere
Melanie Faugere
VAVincent Achour
Vincent Achour
EMEloïse Maakaron
Eloïse Maakaron
CAChristelle Andrieu-Haller
Christelle Andrieu-Haller
CLChristophe Lançon
Christophe Lançon
Psychotropic medications are critical in managing severe mental illnesses (SMI) such as schizophrenia, major depressive disorder (MDD) and bipolar disorder. However, these treatments often lead to adverse side effects that can impair patients' quality of life (QoL) and affect treatment adherence. This study aims to investigate the specific side effects of psychotropic treatments that contribute to a decline in QoL among patients with SMI, independently of treatment adherence. We conducted a cross-sectional study with 1248 patients diagnosed with SMI, recruited from a university psychiatric unit in Marseille, France. QoL was assessed using the Schizophrenia Quality of Life Scale (SQoL-18), and side effects were measured using the UKU Side Effect Rating Scale. Treatment adherence was evaluated using the Medication Adherence Rating Scale (MARS). Statistical analyses included Pearson correlations and multiple linear regression models to identify predictors of QoL. The study found that side effects, as identified by the UKU scores, could significantly predict a reduction in QoL across multiple domains, including multiple dimensions of QoL and the overall QoL index, independent of treatment adherence. Patients on antipsychotics and benzodiazepines reported higher levels of adverse side effects, which correlated with lower QoL scores. An increase in the number of psychotropic treatment classes was also associated with a significant decline in QoL (p < 0.001). Managing psychic side effects and minimising polypharmacy are critical to improving QoL in patients with SMI. Clinicians should consider these factors when developing personalised treatment strategies to enhance patient outcomes.

1 February 2022 in L'Encéphale
Verified
Journal Article
Closed access
guillaume FONDguillaume FOND
guillaume FOND
MMM. Masson
M. Masson
RRR. Richieri
R. Richieri
TKT. Korchia
T. Korchia
DED. Etchecopar-Etchart
D. Etchecopar-Etchart
LBL. Boyer
L. Boyer

1 February 2019 in L'Encéphale
Verified
Journal Article
Closed access
guillaume FONDguillaume FOND
guillaume FOND
MMM. Masson
M. Masson
CLC. Lançon
C. Lançon
PApascal auquier
pascal auquier
LBLaurent Boyer
Laurent Boyer